Clinical Procurement (Fomerly Therapeutic Tendering)
In March 2007, the Chief Medical Officer and Chief Pharmaceutical Officer issued the Circular: Pharmaceutical Clinical Effectiveness – Regional Prescribing Policy. The purpose of the Circular was to –
1. Provide information on the second phase in the Department’s implementation of a product standardisation policy for HSS Boards, Trusts and independent contractors.
Tranche 1 and Tranche 2 products are detailed below.
2. Provide interim advice to promote effective dyslipidaemia management across primary and secondary care.
This guidance is listed below.
3. Provide advice to promote effective use of Proton Pump Inhibitors in the management of symptomatic reflux and / or dyspepsia.
This prescribing guidance is detailed below.
In May 2008 a Circular was issued to provide guidance on the choice of Angiotensin Converting Enzyme(ACE) Inhibitors and Angiotensin-II Receptor Antagonists (A-IIRAs) in primary and secondary care.
This prescibing guidance is detailed below:
In October 2008, a Circular was issued to provide guidance on the choice of Selective Serotonin Re-uptake Inhibitors (SSRIs) in primary and secondary care.
This prescribing guidance is detailed below:
GENERIC MEDICINES TENDER FOR SECONDARY AND PRIMARY CARE SECTORS OF HSC
The Department has been considering proposals for an integrated approach to improved strategies in support of generic prescribing and dispensing. One element of such a strategy will be to develop an explorative regional competitive tendering exercise for the range of generic and branded generic products prescribed in both secondary care and primary care. This is being taken forward under the Pharmaceutical Clinical Effectiveness work streams within CSR 2011.
The initiative will aim to standardise a range of generic products (including branded generics) between the primary and secondary healthcare sectors in order to ensure that patients’ generic medicines are of a uniform presentation thereby optimising their confidence and concordance with these medicines.
The initiative will utilise the STEPS methodology to achieve safe therapeutic economic pharmaceutical selection, securing quality and minimising risk by:
- the pre-qualification of generic companies to agreed criteria;
- quality and risk evaluation of products;
followed by a budget impact assessment enabling the selection of the most economic presentations and/or chemical entities to meet the requisite quality standards. This process will be embedded within an OJEU tender process with a full quality, safety and commercial evaluation across the phased tender process.
This page contains copies of the pre - evaluation presentations to Trade Organisations and Suppliers and a sample of questions and answers related to this initiative.
Please find below a number of useful documents:
